UnknownEarly Phase 1

Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease

30 participantsStarted 2017-07-01

Plain-language summary

hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in management of hemolytic disease of new born

Who can participate

Age range48 Hours – 30 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1)Gestational age more than or equal 37 weeks and postnatal age from 48hr-72hr. 2)Anemia with Reticulocytic count 10% 3)Serum total bilirubin around 18mg/dl . Exclusion Criteria: * 1)perinatal asphyxia. 2)Congenital malformation. 3)Severe respiratory distress. 4)Sepsis during hospital stay. 5)Metabolic problems . 6)Gestational age less than 37 weeks

What they're measuring

To measure duration of phototherapy

Timeframe: Two days

Trial details

NCT IDNCT03130517

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12-31

View on ClinicalTrials.gov More Haemolysis Neonatal trials